VNDA

Business Context and Reporting Period

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on central nervous system disorders. The reporting period covers the three months ended March 31, 2011. The company's primary revenue driver is an amended and restated sublicense agreement with Novartis for the commercialization of Fanapt (iloperidone) in the U.S. and Canada. Vanda retains exclusive rights to Fanapt outside the U.S. and Canada and is developing tasimelteon for sleep and mood disorders.

Key Financial Metrics

Liquidity: As of March 31, 2011, the company held $194.6 million in total cash, cash equivalents, and marketable securities. There is no long-term debt reported; liabilities consist primarily of deferred revenues ($164.0 million) and accrued expenses.

Material Changes vs. Prior Period

• Revenue Decline: Total revenues decreased 39.6% to $7.5 million from $12.4 million. This was driven by the cessation of product sales revenue ($3.7 million in Q1 2010 vs. $0 in Q1 2011) and a decrease in royalty revenue ($2.1 million vs. $0.9 million). Licensing agreement revenue remained flat at $6.6 million.
• Profitability: Net income decreased to $0.1 million from $0.5 million. Income from operations dropped significantly to $0.007 million from $6.1 million due to the loss of product sales and increased operating costs.
• Expense Growth: R&D expenses increased 109% to $4.3 million, primarily due to the initiation of clinical trials for tasimelteon (N24HSWD). G&A expenses increased 15% to $2.9 million, largely due to higher stock-based compensation.
• Cash Flow: Net cash used in operating activities improved to $3.3 million from $4.8 million. Net cash provided by investing activities was $13.2 million, driven by maturities of marketable securities exceeding purchases.

Outlook, Risks, and Management Commentary

• Guidance: Management does not provide specific numerical guidance but expects R&D expenses to increase as clinical trials for tasimelteon continue. They anticipate existing funds will be sufficient to fund planned operations.
• Development Pipeline:
  • Tasimelteon: Two clinical trials for Non-24 Hour Sleep/Wake Disorder (N24HSWD) are underway. A Phase IIb/III trial for Major Depressive Disorder (MDD) is expected to begin in the second half of 2011.
  • Fanapt: Vanda continues to explore regulatory paths for commercialization outside the U.S. and Canada. An application for marketing approval in Australia was accepted for evaluation in November 2010.
• Risks: Key risks include the failure to obtain regulatory approval for tasimelteon, delays in clinical trials, the inability to successfully commercialize Fanapt outside the U.S./Canada, and dependence on Novartis for U.S./Canada commercialization. The company also faces risks related to the realization of deferred tax assets.
• Unusual Items: The company recognized $6.6 million in licensing revenue from the straight-line recognition of the $200 million upfront payment received from Novartis in 2009. This revenue stream is expected to continue until the patent expiration in 2017.

Investor Verification Checklist

• Revenue Sustainability: Verify the timeline for recognizing the remaining deferred revenue from the Novartis upfront payment and the potential for future milestone payments ($265 million).
• Cash Burn Rate: Monitor the rate of cash consumption against the $194.6 million liquidity position, given the increasing R&D spend for tasimelteon trials.
• Clinical Trial Progress: Track enrollment and results of the tasimelteon trials for N24HSWD and the planned MDD trial, as these are critical for future value.
• Novartis Partnership: Assess Novartis's commercial performance of Fanapt in the U.S. and Canada, as this drives royalty revenue and potential milestone triggers.
• International Expansion: Confirm progress on regulatory approvals for Fanapt outside the U.S. and Canada, where Vanda retains exclusive rights.